Coles AJ, et al. – Five–year efficacy and safety of alemtuzumab in patients with active relapsing–remitting multiple sclerosis and inadequate response to prior therapy were evaluated. Through 5 years, alemtuzumab provided durable efficacy in patients with an inadequate response to prior therapy in the absence of continuous treatment.